EUVIMEDEUVIMED entdecken
Crossref

Evaluation of In-Vitro Activity of Plazomicin against Carbapenem Resistant Gram-Negative Bacilli Isolates from a Tertiary Care Hospital in Western India

Preeti Rohilla, Amrutha T. S., Gaurav Salunke, Pradnya Samant, Sanjay Biswas

International Journal of Current Pharmaceutical Review and Research · 15.03.2026 · 18 (03)

DOI: 10.25258/ijcpr.18.3.106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 15.03.2026. Verfasst von Preeti Rohilla und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Carbapenem-resistant Gram-negative bacilli (CR-GNB) significantly compromise therapeutic options in clinical practice. Plazomicin, a next-generation Aminoglycoside, has been structurally optimized to evade most AMEs and retain activity against MDR Enterobacterales, may offer improved activity over conventional aminoglycosides, yet data from the Indian context are limited.

Methods

In this cross-sectional study conducted at a tertiary care cancer hospital in western India from December 2024-January 2025, 100 non-duplicate CR-GNB clinical isolates were evaluated. Antimicrobial susceptibility testing was performed using VITEK-2. Carbapenem isolates were further evaluated for expression of Carbapenemase genes and in vitro susceptibility to Plazomicin and its comparison to other Aminoglycoside.

Results

Plazomicin susceptibility (42%) was significantly higher than amikacin (18%), gentamicin (33%), and tobramycin (13.3%) (p256, MIC₉₀=>256; Escherichia coli MIC₅₀=1, MIC₉₀=>256; Pseudomonas aeruginosa MIC₅₀=12, MIC₉₀=>256; and Enterobacter cloacae MIC₅₀=0.75, MIC₉₀=1. Plazomicin retains potent activity against isolates harboring single carbapenemase genes, while coproduction of multiple resistance determinants- especially NDM with OXA-48 markedly diminishes susceptibility and results in elevated MIC values.

Conclusions

Plazomicin shows superior in vitro activity compared to conventional aminoglycosides against selected CR-GNB isolates. Resistance genotypes markedly influence plazomicin susceptibility, highlighting the role of molecular characterisation in guiding antimicrobial therapy.

Zitieren

APA

Rohilla, P., S., A. T., Salunke, G., Samant, P., & Biswas, S. (2026). Evaluation of In-Vitro Activity of Plazomicin against Carbapenem Resistant Gram-Negative Bacilli Isolates from a Tertiary Care Hospital in Western India. International Journal of Current Pharmaceutical Review and Research, 18(03). https://doi.org/10.25258/ijcpr.18.3.106

Vancouver

Rohilla P, S. AT, Salunke G, Samant P, Biswas S. Evaluation of In-Vitro Activity of Plazomicin against Carbapenem Resistant Gram-Negative Bacilli Isolates from a Tertiary Care Hospital in Western India. International Journal of Current Pharmaceutical Review and Research. 2026;18(03). doi:10.25258/ijcpr.18.3.106

BibTeX
@article{Rohilla2026,
  author = {Rohilla, Preeti and S., Amrutha T. and Salunke, Gaurav and Samant, Pradnya and Biswas, Sanjay},
  title = {Evaluation of In-Vitro Activity of Plazomicin against Carbapenem Resistant Gram-Negative Bacilli Isolates from a Tertiary Care Hospital in Western India},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {03},
  doi = {10.25258/ijcpr.18.3.106}
}
Kostenlos starten →